Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined. How can sponsors keep pace with this rapidly growing market and avoid costly delays that can threaten critical timelines?
Explore the analysis of a recent industry study examining sponsors’ most common roadblocks in cell and gene therapy development and the technology solutions that can help overcome them.
You’ll discover insights like:
1. Biopharma Dive, 5 questions facing gene therapy in 2023 (2023)
Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific
This download should complete shortly. If the resource doesn't automatically download, please, click here.